Olaf Stüve (Olaf Stϋve, Olaf Stuve)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 38

Top Topics

Anti Inflammatory Drugs

Lipopolysaccharide Induced

Top Venues

Therapeutic advances in neurological disorders

Proceedings of the National Academy of Sciences of the United States of America

Science immunology

Journal of central nervous system disease

This page only lists publications with an associated author ORCID identifier.

Publications

Laura Airas, Robert A Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stüve, Mitzi J Williams, Bernd C Kieseier, Heinz Wiendl
A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis. Therapeutic advances in neurological disorders 17 (2024)
Afsaneh Shirani, Anne H Cross, Olaf Stüve
Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database. Therapeutic advances in neurological disorders 17 (2024)
Peter V Sguigna, Rehana Z Hussain, Annette Okai, Kyle M Blackburn, Lauren Tardo, Mariam Madinawala, Julie Korich, Lori A Lebson, Jeffrey Kaplan, Salter Amber, Navid Manouchehri, Olaf Stüve
Cladribine tablets after treatment with natalizumab (CLADRINA) - rationale and design. Therapeutic advances in neurological disorders 17 (2024)
William A Miller-Little, Xing Chen, Vanessa Salazar, Caini Liu, Katarzyna Bulek, Julie Y Zhou, Xiao Li, Olaf Stüve, Thaddeus S Stappenbeck, George R Dubyak, Junjie Zhao, Xiaoxia Li
A T H 17-intrinsic IL-1β-STAT5 axis drives steroid resistance in autoimmune neuroinflammation. Science immunology 9 (95) (2024)
William A Miller-Little, Xing Chen, Vanessa Salazar, Caini Liu, Katarzyna Bulek, Julie Y Zhou, Xiao Li, Olaf Stüve, Thaddeus S Stappenbeck, George R Dubyak, Junjie Zhao, Xiaoxia Li
A T H 17-intrinsic IL-1β-STAT5 axis drives steroid resistance in autoimmune neuroinflammation. Science immunology 9 (95) (2024)
Laura Airas, Robert A Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stüve, Mitzi J Williams, Bernd C Kieseier, Heinz Wiendl
A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis. Therapeutic advances in neurological disorders 17 (2024)
William A Miller-Little, Xing Chen, Vanessa Salazar, Caini Liu, Katarzyna Bulek, Julie Y Zhou, Xiao Li, Olaf Stüve, Thaddeus S Stappenbeck, George R Dubyak, Junjie Zhao, Xiaoxia Li
A T H 17-intrinsic IL-1β-STAT5 axis drives steroid resistance in autoimmune neuroinflammation. Science immunology 9 (95) (2024)
Afsaneh Shirani, Anne H Cross, Olaf Stüve
Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database. Therapeutic advances in neurological disorders 17 (2024)
Laura Airas, Robert A Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stüve, Mitzi J Williams, Bernd C Kieseier, Heinz Wiendl
A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis. Therapeutic advances in neurological disorders 17 (2024)
Peter V Sguigna, Rehana Z Hussain, Annette Okai, Kyle M Blackburn, Lauren Tardo, Mariam Madinawala, Julie Korich, Lori A Lebson, Jeffrey Kaplan, Salter Amber, Navid Manouchehri, Olaf Stüve
Cladribine tablets after treatment with natalizumab (CLADRINA) - rationale and design. Therapeutic advances in neurological disorders 17 (2024)
Navid Manouchehri, Victor H Salinas, Rehana Z Hussain, Olaf Stüve
Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Barbara Elena Stopschinski, Rick A Weideman, Danni McMahan, David A Jacob, Bertis B Little, Hsueh-Sheng Chiang, Nil Saez-Calveras, Olaf Stüve
Microglia as a cellular target of diclofenac therapy in Alzheimer's disease. Therapeutic advances in neurological disorders 16 (2023)
Meredith A Bryarly, Michael A Rubin, Olaf Stüve
Perspective: Industry-patient relationships for the promotion of pharmaceutical agents. Therapeutic advances in neurological disorders 16 (2023)
Barbara Elena Stopschinski, Rick A Weideman, Danni McMahan, David A Jacob, Bertis B Little, Hsueh-Sheng Chiang, Nil Saez-Calveras, Olaf Stüve
Microglia as a cellular target of diclofenac therapy in Alzheimer's disease. Therapeutic advances in neurological disorders 16 (2023)
Navid Manouchehri, Victor H Salinas, Rehana Z Hussain, Olaf Stüve
Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Navid Manouchehri, Victor H Salinas, Rehana Z Hussain, Olaf Stüve
Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Navid Manouchehri, Victor H Salinas, Rehana Z Hussain, Olaf Stüve
Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Navid Manouchehri, Victor H Salinas, Rehana Z Hussain, Olaf Stüve
Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Navid Manouchehri, Victor H Salinas, Rehana Z Hussain, Olaf Stüve
Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Navid Manouchehri, Victor H Salinas, Rehana Z Hussain, Olaf Stüve
Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Darin T Okuda, Orhun H Kantarci, Christine Lebrun-Frénay, Maria Pia Sormani, Christina J Azevedo, Francesca Bovis, Le H Hua, Lilyana Amezcua, Ellen M Mowry, Christophe Hotermans, Jason Mendoza, John S Walsh, Christian von Hehn, Wendy S Vargas, Stacy Donlon, Robert T Naismith, Annette Okai, Gabriel Pardo, Pavle Repovic, Olaf Stüve, Aksel Siva, Daniel Pelletier
Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. Annals of neurology (2022)
Samra Vazirian, Travis Ho, Rick A Weideman, Meagen R Salinas, Paul W Hurd, Olaf Stüve
Utilization of a neurology specialty service by primary care providers for headache management at a tertiary care hospital. Journal of central nervous system disease 14 (2022)
Navid Manouchehri, Afsaneh Shirani, Victor H Salinas, Lauren Tardo, Rehana Z Hussain, David Pitt, Olaf Stüve
Clinical trials in multiple sclerosis: past, present, and future. Neurologia i neurochirurgia polska 56 (3) (2022)
Laurent Calvier, Navid Manouchehri, Anastasia Sacharidou, Chieko Mineo, Philip W Shaul, David Y Hui, Maria Z Kounnas, Olaf Stüve, Joachim Herz
Apolipoprotein E receptor 2 deficiency decreases endothelial adhesion of monocytes and protects against autoimmune encephalomyelitis. Science immunology 6 (62) (2022)
Anthony T Reder, Olaf Stüve, Stephanie K Tankou, Thomas P Leist
T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy. Multiple sclerosis (Houndmills, Basingstoke, England) (2022)
Rehana Z Hussain, Peter V Sguigna, Annette Okai, Crystal Wright, Mariam Madinawala, Ann D Bass, Gary R Cutter, Navid Manouchehri, Olaf Stüve
The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives. Journal of central nervous system disease 14 (2022)
Natalia Gonzalez Caldito, Shirley O'Leary, Olaf Stüve
Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation. Multiple sclerosis (Houndmills, Basingstoke, England) 27 (8) (2021)
Navid Manouchehri, Rehana Z Hussain, Petra D Cravens, Ekaterina Esaulova, Maxim N Artyomov, Brian T Edelson, Gregory F Wu, Anne H Cross, Richard Doelger, Nicolas Loof, Todd N Eagar, Thomas G Forsthuber, Laurent Calvier, Joachim Herz, Olaf Stüve
CD11c+CD88+CD317+ myeloid cells are critical mediators of persistent CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 118 (14) (2021)
Navid Manouchehri, Olaf Stüve
Choroid plexus volumetrics and brain inflammation in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 118 (40) (2021)
Victor H Salinas, Olaf Stüve
Systems Approaches to Unravel T Cell Function and Therapeutic Potential in Autoimmune Disease. Journal of immunology (Baltimore, Md. : 1950) 206 (4) (2021)
Yinan Zhang, Amber Salter, Shan Jin, William J Culpepper, Gary R Cutter, Mitchell Wallin, Olaf Stüve
Disease-modifying therapy prescription patterns in people with multiple sclerosis by age. Therapeutic advances in neurological disorders 14 (2021)
Navid Manouchehri, Olaf Stüve
Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment. Therapeutic advances in neurological disorders 14 (2021)
Afsaneh Shirani, Scott R Dalton, Eric J Avery, Lakshman Arcot Jayagopal, Christina Meyer, Olaf Stüve, Rana Zabad
Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report. Journal of central nervous system disease 13 (2021)
Yinan Zhang, Natalia Gonzalez Caldito, Afsaneh Shirani, Amber Salter, Gary Cutter, William Culpepper, Mitchell Wallin, Peter Kosa, Bibiana Bielekova, Fred Lublin, Olaf Stüve
Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. Therapeutic advances in neurological disorders 13 (2020)
Navid Manouchehri, Olaf Stüve
Trials and therapies in secondary progressive MS, simplified. Nature reviews. Neurology 15 (8) (2020)
Olaf Stüve, Rick A Weideman, Danni M McMahan, David A Jacob, Bertis B Little
Diclofenac reduces the risk of Alzheimer's disease: a pilot analysis of NSAIDs in two US veteran populations. Therapeutic advances in neurological disorders 13 (2020)
Natalia Gonzalez Caldito, Afsaneh Shirani, Salter Amber, Olaf Stüve
Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database. Multiple sclerosis (Houndmills, Basingstoke, England) 27 (7) (2020)
Olaf Stüve, Per Soelberg Soerensen, Thomas Leist, Gavin Giovannoni, Yann Hyvert, Doris Damian, Fernando Dangond, Ursula Boschert
Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Therapeutic advances in neurological disorders 12 (2019)